PET radiopharmaceuticals in radiation treatment planning - Synthesis and biological characteristics

被引：36

作者：

Haubner, Roland ^{[1
]}

机构：

[1] Med Univ Innsbruck, Innsbruck, Austria

来源：

RADIOTHERAPY AND ONCOLOGY | 2010年 / 96卷 / 03期

关键词：

Glucose metabolism; Amino acid metabolism; Hypoxia; Proliferation; Lipid metabolism; Angiogenesis; SSTR expression; POSITRON-EMISSION-TOMOGRAPHY; INTEGRIN ALPHA(V)BETA(3) EXPRESSION; SQUAMOUS-CELL CARCINOMA; PROLIFERATION IN-VIVO; PROSTATE-CANCER; ALPHA-V-BETA-3; INTEGRIN; NEUROENDOCRINE TUMORS; SUBSTRATE-SPECIFICITY; CLINICAL-APPLICATIONS; AUTOMATED SYNTHESIS;

D O I：

10.1016/j.radonc.2010.07.022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

During the last decade several different PET radiopharmaceuticals entered into the clinic and positron emission tomography (PET) became an important tool for staging of cancer patients and assessing response to therapy. Meanwhile FDG-PET has also found application in radiation treatment planning. Potential radiopharmaceuticals for radiation treatment planning may also include tracers allowing monitoring of proliferation, amino acid metabolism, hypoxia, lipid metabolism and receptor expression. Here the syntheses of a selection of clinically tested promising tracers are summarized and the different molecular mechanisms for accumulation are discussed which may help to choose the appropriate tracer for planning radiation treatment strategies. (C) 2010 European Society for Therapeutic Radiology and Oncology and European Association of Nuclear Medicine. Published by Elsevier Ireland Ltd. All rights reserved. 96 (2010) 280-287

引用

页码：280 / 287

页数：8

共 69 条

[1]

ARORA KK, 1990, J BIOL CHEM, V265, P6481

[2] Validation of 68Ge/68Ga generator processing by chemical purification for routine clinical application of 68Ga-DOTATOC [J].